Drugs / HB0025
HB0025
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04678908 | Mar 2021 → Feb 2024 | cancer | Huabo Biopharm Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06758557 | Jan 2024 → Oct 2025 overdue | endometrial cancer, non-small cell lung carcinoma | Huabo Biopharm Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07376629 | Aug 2025 → Jan 2027 expected | triple-negative breast carcinoma | Huabo Biopharm Co., Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06222125 | Jan 2023 → Jan 2025 | kidney cancer | Huabo Biopharm Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07383116 | Jan 2026 → Apr 2028 expected | non-small cell lung carcinoma | Shanghai Huaota Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB0025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07383116 ↗ |
| Known as | Recombinant Humanized Anti-PD-L1 Monoclonal Antibody-VEGFR1 Fusion Protein | “Recombinant Humanized Anti-PD-L1 Monoclonal Antibody-VEGFR1 Fusion Protein” NCT04678908 ↗ |
| Action | Inhibit | “anti-programmed cell death-ligand 1（Anti-PD-L1）” NCT06222125 ↗ |
| Modality | Monoclonal antibody | “Recombinant Humanized Anti-PD-L1 Monoclonal Antibody-VEGFR1 Fusion Protein” NCT04678908 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT04678908 ↗ |